MDT

89.79

+2.42%↑

VEEV

231.54

-1.1%↓

A

116.76

+0.09%↑

HQY

88.37

+1.59%↑

PDCO

31.24

+0.03%↑

MDT

89.79

+2.42%↑

VEEV

231.54

-1.1%↓

A

116.76

+0.09%↑

HQY

88.37

+1.59%↑

PDCO

31.24

+0.03%↑

MDT

89.79

+2.42%↑

VEEV

231.54

-1.1%↓

A

116.76

+0.09%↑

HQY

88.37

+1.59%↑

PDCO

31.24

+0.03%↑

MDT

89.79

+2.42%↑

VEEV

231.54

-1.1%↓

A

116.76

+0.09%↑

HQY

88.37

+1.59%↑

PDCO

31.24

+0.03%↑

MDT

89.79

+2.42%↑

VEEV

231.54

-1.1%↓

A

116.76

+0.09%↑

HQY

88.37

+1.59%↑

PDCO

31.24

+0.03%↑

Search

Bristol-Myers Squibb Co.

Closed

SectorHealthcare

60.99 1.65

Overview

Share price change

24h

Current

Min

59.86

Max

61.57

Key metrics

By Trading Economics

Income

-1.1B

76M

Sales

442M

12B

P/E

Sector Avg

14.05

73.239

EPS

1.67

Dividend yield

4.06

Profit margin

0.616

Employees

34,100

EBITDA

-1.9B

2.6B

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+1.52% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.06%

3.06%

Next Earnings

24 kwi 2025

Next Dividend date

1 maj 2025

Next Ex Dividend date

4 kwi 2025

Market Stats

By TradingEconomics

Market Cap

-744M

120B

Previous open

59.34

Previous close

60.99

News Sentiment

By Acuity

33%

67%

89 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Bristol-Myers Squibb Co. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

11 mar 2025, 10:13 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11 mar 2025, 10:13 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

6 lut 2025, 12:13 UTC

Earnings

Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook

14 mar 2025, 09:30 UTC

Top News

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

11 mar 2025, 02:26 UTC

Acquisitions, Mergers, Takeovers

Abecma Is an Immunotherapy Indicated for Treatment of Relapsed or Refractory Multiple Myeloma >TSVT

11 mar 2025, 02:26 UTC

Acquisitions, Mergers, Takeovers

Stockholders Owning About 5.3% of 2seventy Bio Shares Have Agreed to Tender All Their Shares >TSVT

11 mar 2025, 02:26 UTC

Acquisitions, Mergers, Takeovers

2seventy Bio CEO: Rationale for Deal Clear, in Line With Focus on Unlocking Value of Abecma >TSVT

11 mar 2025, 02:23 UTC

Acquisitions, Mergers, Takeovers

2seventy Bio Stock Will No Longer Trade on Nasdaq After Closing of Deal, Expected in 2Q >TSVT

11 mar 2025, 02:22 UTC

Acquisitions, Mergers, Takeovers

2seventy Bio's Board Unanimously Recommends Stockholders Tender Shares in Offer >TSVT

11 mar 2025, 02:21 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers Deal Represents 88% Premium to 2seventy Closing Price of $2.66 on March 7 >TSVT

11 mar 2025, 02:21 UTC

Acquisitions, Mergers, Takeovers

Bristol Myers to Acquire 2seventy Bio Shares at $5.00 Each in All-Cash Deal for Equity Value of About $286M >TSVT

11 mar 2025, 02:19 UTC

Acquisitions, Mergers, Takeovers

2seventy Bio Enters Into Definitive Agreement to Be Acquired by Bristol Myers Squibb

28 lut 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6 lut 2025, 15:35 UTC

Earnings

Bristol Myers Wallops Fourth-Quarter Views, But Shares Slide On 2025 Outlook -- IBD

6 lut 2025, 13:56 UTC

Earnings

Bristol Myers Wallops Fourth-Quarter Earnings Views. But Shares Plummet 5%. -- IBD

6 lut 2025, 13:25 UTC

Top News
Earnings

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6 lut 2025, 12:00 UTC

Earnings

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

6 lut 2025, 11:59 UTC

Earnings

Bristol-Myers Squibb 4Q Gross Margin 61.0% >BMY

6 lut 2025, 11:59 UTC

Earnings

Bristol-Myers Squibb 4Q Rev $12.3B >BMY

6 lut 2025, 11:59 UTC

Earnings

Bristol-Myers Squibb 4Q Net $72M >BMY

6 lut 2025, 11:59 UTC

Earnings

Bristol-Myers Squibb 4Q EPS 4c >BMY

6 lut 2025, 11:59 UTC

Earnings

Bristol-Myers Squibb 4Q Adj EPS $1.67 >BMY

6 lut 2025, 11:59 UTC

Earnings

Bristol Myers Squibb: Expanding Existing Strategic Productivity Initiative to Include About $2B in Additional Annualized Cost Savings by the End of 2027 >BMY

6 lut 2025, 11:59 UTC

Earnings

Bristol Myers Squibb 4Q International Revenue Rose 5% to $3.7B >BMY

6 lut 2025, 11:59 UTC

Earnings

Bristol Myers Squibb 4Q U.S. Revenue Rose 9% to $8.6B >BMY

6 lut 2025, 11:59 UTC

Earnings

Bristol Myers Squibb 4Q Legacy Portfolio Revenue $5.98B, Down 4% >BMY

6 lut 2025, 11:59 UTC

Earnings

Bristol Myers Squibb: 4Q Growth Portfolio Revenue Primarily Due to Higher Demand for Reblozyl, Breyanzi, Camzyos, Yervoy and Opdualag >BMY

6 lut 2025, 11:59 UTC

Earnings

Bristol Myers Squibb 4Q Rev $12.34B >BMY

6 lut 2025, 11:59 UTC

Earnings

Bristol Myers Squibb: 4Q Legacy Portfolio Revenue Lower Vs Yr-Ago Primarily Due to Impact of Generics on Sprycel, Revlimid, Abraxane and Pomalyst, Partially Offset by Higher Demand for Eliquis >BMY

6 lut 2025, 11:59 UTC

Earnings

Bristol Myers Squibb: 2025 Rev Outlook Reflects Near-Term Impact of Generics Across Revlimid, Pomalyst, Sprycel and Abraxane >BMY

Peer Comparison

Price change

Bristol-Myers Squibb Co. Forecast

Price Target

By TipRanks

1.52% upside

12 Months Forecast

Average 60.93 USD  1.52%

High 70 USD

Low 37 USD

Based on 16 Wall Street analysts offering 12 month price targets forBristol-Myers Squibb Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

16 ratings

5

Buy

10

Hold

1

Sell

Technical Score

By Trading Central

59.99 / 61.34Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

89 / 386 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.